| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Boh-Ram Kim, Kyungsil Yoon, Hyun-Jung Byun, Seung Hee Seo, Seung-Hoon Lee, Seung Bae Rh. The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways. Oncotarget. vol 5. issue 15. 2015-12-21. PMID:25153728. |
in addition, the phosphoinositide-3-kinase (pi3k)/akt/mammalian target of rapamycin (mtor) pathway was strongly inhibited by the combined treatment, showing de-repression of the tuberous sclerosis complex (tsc) and suppression of ras homolog enriched in the brain (rheb) and mtor and raptor in aggressive ovarian carcinoma cells and mouse xenograft models. |
2015-12-21 |
2023-08-13 |
mouse |
| Adam P Ostendorf, Michael Won. mTOR inhibition in epilepsy: rationale and clinical perspectives. CNS drugs. vol 29. issue 2. 2015-11-17. PMID:25633849. |
currently, larger controlled studies are underway using mtor inhibitors in individuals with tuberous sclerosis complex and intractable epilepsy. |
2015-11-17 |
2023-08-13 |
Not clear |
| Paolo Curatol. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatric neurology. vol 52. issue 3. 2015-11-12. PMID:25591831. |
mechanistic target of rapamycin (mtor) in tuberous sclerosis complex-associated epilepsy. |
2015-11-12 |
2023-08-13 |
Not clear |
| Paolo Curatol. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatric neurology. vol 52. issue 3. 2015-11-12. PMID:25591831. |
recent preclinical and clinical studies have increased interest in the potential role of mtor inhibitors for the treatment of tuberous sclerosis complex-related epilepsy. |
2015-11-12 |
2023-08-13 |
Not clear |
| Xin Wu, Yannong Dou, Yan Yang, Difei Bian, Jinque Luo, Bei Tong, Yufeng Xia, Yue Da. Arctigenin exerts anti-colitis efficacy through inhibiting the differentiation of Th1 and Th17 cells via an mTORC1-dependent pathway. Biochemical pharmacology. vol 96. issue 4. 2015-11-09. PMID:26074264. |
interestingly, the inhibitory effect of arctigenin on t cell differentiation disappeared under a status of mtorc1 overactivation via knockdown of tuberous sclerosis complex 2 (tsc2, a negative regulator of mtorc1) or pretreatment of leucine (an agonist of mtor). |
2015-11-09 |
2023-08-13 |
mouse |
| James W Wheles. Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy. Epilepsy & behavior case reports. vol 4. 2015-11-06. PMID:26543807. |
use of the mtor inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy. |
2015-11-06 |
2023-08-13 |
Not clear |
| James W Wheles. Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy. Epilepsy & behavior case reports. vol 4. 2015-11-06. PMID:26543807. |
tuberous sclerosis complex (tsc) is a genetic disease in which overactivation of mechanistic target of rapamycin (mtor) signaling leads to the growth of benign hamartomas in multiple organs, including the brain, and is associated with a high rate of epilepsy and neurological deficits. |
2015-11-06 |
2023-08-13 |
Not clear |
| Vehbi Doğan, Şule Yeşil, Şeyma Kayalı, Serdar Beken, Senem Özgür, İlker Ertuğrul, Ceyhun Bozkurt, Utku Arman Örün, Selmin Karademi. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus. Journal of tropical pediatrics. vol 61. issue 1. 2015-11-03. PMID:25344617. |
mutations in tsc-1/tsc-2 genes result in increased mammalian target of rapamycin (mtor) pathway activation responsible for the hamartomatous lesions of tuberous sclerosis complex. |
2015-11-03 |
2023-08-13 |
Not clear |
| Vehbi Doğan, Şule Yeşil, Şeyma Kayalı, Serdar Beken, Senem Özgür, İlker Ertuğrul, Ceyhun Bozkurt, Utku Arman Örün, Selmin Karademi. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus. Journal of tropical pediatrics. vol 61. issue 1. 2015-11-03. PMID:25344617. |
in this report we present a case with multiple symptomatic rhabdomyomas associated with tuberous sclerosis complex, deemed to be ineligible for surgical removal, treated with everolimus (mtor inhibitor). |
2015-11-03 |
2023-08-13 |
Not clear |
| Joanna Trelinska, Iwona Dachowska, Katarzyna Kotulska, Wojciech Fendler, Sergiusz Jozwiak, Wojciech Mlynarsk. Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening. Anti-cancer drugs. vol 26. issue 4. 2015-11-03. PMID:25719621. |
the aim of this study was to evaluate the most common adverse events (aes) linked to everolimus therapy, a mammalian target of rapamycin (mtor) inhibitor, in children and adolescents with tuberous sclerosis complex (tsc) hospitalized in one medical center. |
2015-11-03 |
2023-08-13 |
human |
| Danielle R Weidman, Jason D Pole, Eric Bouffet, Michael D Taylor, Ute Bartel. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). Pediatric blood & cancer. vol 62. issue 10. 2015-11-02. PMID:25929843. |
dose-level response rates of mtor inhibition in tuberous sclerosis complex (tsc) related subependymal giant cell astrocytoma (sega). |
2015-11-02 |
2023-08-13 |
Not clear |
| A Tarasewicz, A Dębska-Ślizień, M Bułanowski, A Więcek, B Rutkowsk. Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report. Transplantation proceedings. vol 46. issue 8. 2015-10-26. PMID:25380949. |
tuberous sclerosis complex (tsc) is an inherited disorder caused by mutations of tsc1 or tsc2 genes, resulting in constitutive activation of the mammalian target of rapamycin (mtor) and impairment of the cell cycle. |
2015-10-26 |
2023-08-13 |
Not clear |
| Dong Liu, Yongqing Zhang, Robert Gharavi, Hee Ra Park, Jaewon Lee, Sana Siddiqui, Richard Telljohann, Matthew R Nassar, Roy G Cutler, Kevin G Becker, Mark P Mattso. The mitochondrial uncoupler DNP triggers brain cell mTOR signaling network reprogramming and CREB pathway up-regulation. Journal of neurochemistry. vol 134. issue 4. 2015-10-19. PMID:26010875. |
gene expression profiling of the cerebral cortex of dnp-treated mice revealed reprogramming of signaling cascades that included suppression of the mammalian target of rapamycin (mtor) and insulin--pi3k - mapk pathways, and up-regulation of tuberous sclerosis complex 2, a negative regulator of mtor. |
2015-10-19 |
2023-08-13 |
mouse |
| Duyu Nie, Zehua Chen, Darius Ebrahimi-Fakhari, Alessia Di Nardo, Kristina Julich, Victoria K Robson, Yung-Chih Cheng, Clifford J Woolf, Myriam Heiman, Mustafa Sahi. The Stress-Induced Atf3-Gelsolin Cascade Underlies Dendritic Spine Deficits in Neuronal Models of Tuberous Sclerosis Complex. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 35. issue 30. 2015-10-16. PMID:26224859. |
hyperactivation of the mechanistic target of rapamycin (mtor) kinase, as a result of loss-of-function mutations in tuberous sclerosis complex 1 (tsc1) or tsc2 genes, causes protein synthesis dysregulation, increased cell size, and aberrant neuronal connectivity. |
2015-10-16 |
2023-08-13 |
mouse |
| Lieke M C Gijezen, Marigje Vernooij, Herm Martens, Charlene E U Oduber, Charles J M Henquet, Theo M Starink, Martin H Prins, Fred H Menko, Patty J Nelemans, Maurice A M van Steense. Topical rapamycin as a treatment for fibrofolliculomas in Birt-Hogg-Dubé syndrome: a double-blind placebo-controlled randomized split-face trial. PloS one. vol 9. issue 6. 2015-10-06. PMID:24910976. |
topical use of the mtor inhibitor rapamycin is an effective treatment for the skin tumours (angiofibromas) in tuberous sclerosis complex, which is also characterised by mtor deregulation. |
2015-10-06 |
2023-08-13 |
Not clear |
| Lin Zhang, Ke Li, Hong He, Mao-qing H. [Tsc1 promoter methylation rate, mTOR expression in food-induced obese rat hypothalamus]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition. vol 46. issue 1. 2015-09-25. PMID:25807795. |
to investigate the methylation rate of tuberous sclerosis complex 1 (tsc1) promoter and expression of mammalian target of rapamycin (mtor) in food-induced rat hypothalamus. |
2015-09-25 |
2023-08-13 |
rat |
| Nicholas Rensing, Lirong Han, Michael Won. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex. Epilepsia. vol 56. issue 7. 2015-09-16. PMID:26122303. |
inhibitors of the mechanistic target of rapamycin (mtor) pathway have antiepileptogenic effects in preventing epilepsy and pathologic and molecular mechanisms of epileptogenesis in mouse models of tuberous sclerosis complex (tsc). |
2015-09-16 |
2023-08-13 |
mouse |
| Paolo Curatolo, Romina Moavero, Petrus J de Vrie. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. The Lancet. Neurology. vol 14. issue 7. 2015-08-26. PMID:26067126. |
the surveillance and management guidelines and clinical criteria for tuberous sclerosis were revised in 2012, and mtor inhibitors are now recommended as treatment options for subependymal giant cell astrocytomas and renal angiomyolipomas-two common features of the disease. |
2015-08-26 |
2023-08-13 |
Not clear |
| Guido Martignoni, Maurizio Pea, Claudia Zampini, Matteo Brunelli, Diego Segala, Giuseppe Zamboni, Franco Bonett. PEComas of the kidney and of the genitourinary tract. Seminars in diagnostic pathology. vol 32. issue 2. 2015-08-17. PMID:25804448. |
the genetic alterations of tuberous sclerosis complex that promote activation of the mtor pathway have been identified in pecomas. |
2015-08-17 |
2023-08-13 |
human |
| Irmina Grzegorek, Ewa Zuba-Surma, Mariusz Chabowski, Dariusz Janczak, Andrzej Szuba, Piotr Dziegie. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis. Anticancer research. vol 35. issue 6. 2015-08-06. PMID:26026094. |
it is caused by a mutation in one of the tuberous sclerosis genes, tsc1 or tsc2, and constitutive activation of the mammalian target of rapamycin (mtor) pathway in smooth muscle-like cells (lam cells). |
2015-08-06 |
2023-08-13 |
Not clear |